Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 185.18% | 240.14% | 124.62% | -30.11% | -70.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.18% | 240.14% | 124.62% | -30.11% | -70.39% |
| Cost of Revenue | 162.01% | 249.85% | 122.33% | 24.91% | -23.08% |
| Gross Profit | 205.88% | 233.80% | 126.41% | -49.52% | -80.78% |
| SG&A Expenses | -47.36% | -27.41% | -8.86% | -4.35% | -6.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.63% | -21.41% | -13.06% | -9.31% | -9.38% |
| Operating Income | 62.60% | 42.15% | 25.50% | 4.59% | -14.80% |
| Income Before Tax | 44.50% | 27.28% | 27.34% | 18.81% | 4.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.50% | 27.28% | 27.34% | 18.81% | 4.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.50% | 27.28% | 27.34% | 18.81% | 4.16% |
| EBIT | 62.60% | 42.15% | 25.50% | 4.59% | -14.80% |
| EBITDA | 69.01% | 45.22% | 25.54% | 4.54% | -14.91% |
| EPS Basic | 44.38% | 26.71% | 26.67% | 18.13% | 3.61% |
| Normalized Basic EPS | 54.00% | 36.63% | 21.15% | 18.42% | 3.85% |
| EPS Diluted | 44.38% | 26.71% | 26.67% | 18.13% | 3.61% |
| Normalized Diluted EPS | 54.00% | 36.63% | 21.15% | 18.42% | 3.85% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |